微流控装置捕获的循环肿瘤细胞(CTC)在上皮性卵巢癌患者中的预测价值
前瞻性研究纳入54例上皮性卵巢癌患者,用导电纳米粗糙微流控芯片捕获CTC,检出率98.1%(53/54)。CTC计数与肿瘤分期及血清CA125水平无显著差异,但无进展生存期在≥3个CTC截点下降,CTC簇阳性与铂耐药相关。
要点
- CTC检出率98.1%(53/54),初诊与复发患者中位单CTC计数分别为4(0-13)和3(1-9)。
- CTC计数与肿瘤分期及血清CA125水平无显著差异。
- 无进展生存期在≥3个CTC截点下降,CTC簇阳性与铂耐药相关。
核心结论
- 该研究为基于导电纳米粗糙微流控平台设计用于捕获上皮性卵巢癌患者CTC的芯片提供了概念验证。
- 需要更大的患者采样量和更长的随访时间来确定其临床适用性。
研究设计与样本
- 前瞻性研究,2014年8月至2015年5月共纳入54例上皮性卵巢癌患者。
- 在外周血中于原发肿瘤切除前及复发疾病开始辅助化疗前检测CTC。
- CTC定义为EpCAM阳性、DAPI阳性且CD45阴性。
主要发现
- 初诊患者24例,复发患者30例。
- CTC检出率98.1%(53/54)。
- 初诊患者中位单CTC计数为4(0-13),中位CTC簇计数为1(0-14)。
- 复发患者中位单CTC计数为3(1-9),中位CTC簇计数为1(0-24)。
- CTC计数与肿瘤分期或血清CA125水平无显著差异;无进展生存期在≥3个CTC截点下降,CTC簇阳性与铂耐药相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要更大的患者采样量和更长的随访时间来确定其临床适用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To test an electrically conductive chip, incorporating a nanoroughened microfluidic platform for the capture of circulating tumor cells (CTCs), and assess its clinical merit in instances of epithelial ovarian cancer (EOC). METHODS: A total of 54 patients with EOC recruited between August 2014 and May 2015 were enrolled in this prospective study. CTCs in peripheral blood were detected in advance of primary tumor resection and before initiating adjuvant chemotherapy for recurrent disease. We identified CTCs as EpCAM-positive and DAPI-positive, and CD45-negative feature. RESULTS: Twenty-four patients with primary disease and 30 patients with recurrences were included in the study. CTCs were detected in 98.1% (53/54). In newly diagnosed patients, median counts of single CTCs and CTC clusters were 4 (0-13) and 1(0-14), respectively. In those with recurrences, median counts were 3 (1-9) and 1(0-24), respectively. Such counts did not differ significantly by tumor stage or by serum CA125 level; but progression-free survival declined at a cutpoint of ≥3 CTCs, and CTC-cluster positivity correlated with platinum resistance. Isolated CTCs (successfully cultured ex vivo in two patients) showed greater sensitivity to anticancer drugs and proliferated more rapidly than did established cell lines. CONCLUSION: Proof-of-concept was provided for an electrically conductive and nanoroughened microfluidic platform-based chip designed to capture CTCs in patients with EOC. A larger patient sampling and longer duration of follow-up are needed to determine its suitability for clinical use.
引用
- Lee M, Kim EJ, Cho Y, et al. Predictive value of circulating tumor cells (CTCs) captured by microfluidic device in patients with epithelial ovarian cancer. Gynecol Oncol. 2017. PMID: 28274569. doi:10.1016/j.ygyno.2017.02.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。